Loading Dose Regimens for Acute Myocardial Infarction

Antiplatelet Loading Doses

• Aspirin 162–325 mg oral loading dose should be given immediately to all adults with acute MI (both STEMI and NSTEMI) [1][2]
• Aspirin maintenance dose of 75–100 mg daily (81 mg preferred when combined with ticagrelor) [3][4]2
• Ticagrelor 180 mg oral loading dose (followed by 90 mg twice daily) is the first‑line P2Y12 inhibitor for patients at moderate‑to‑high risk (elevated troponins) regardless of initial treatment strategy [3][4]
• Ticagrelor can be started in patients already receiving clopidogrel; clopidogrel should be discontinued when ticagrelor is initiated [3][4]
• Ticagrelor requires no dose adjustment for renal impairment [3][4]
• Contraindications to ticagrelor include prior intracranial hemorrhage and active bleeding [3][4]
• Prasugrel 60 mg oral loading dose (maintenance 10 mg daily, reduced to 5 mg if body weight <60 kg) should be administered only after coronary anatomy is known and the patient is proceeding to PCI [3][1]
• Prasugrel is contraindicated in patients with prior stroke/TIA, age ≥ 75 years, body weight < 60 kg, prior intracranial hemorrhage, or active bleeding [3][4]
• Clopidogrel loading dose of 300–600 mg oral (600 mg preferred for rapid platelet inhibition) is a third‑line option when ticagrelor or prasugrel are contraindicated or when oral anticoagulation is required [3][4]2
• In patients > 75 years receiving fibrinolysis, a reduced clopidogrel loading dose of 75 mg is recommended (no loading dose in this age group otherwise) 1
• Clopidogrel maintenance dose is 75 mg daily [3][4]2

Anticoagulation Loading Doses

• Unfractionated heparin (UFH): weight‑based 60 U/kg IV bolus (max 4000 U) followed by 12 U/kg/h infusion (max 1000 U/h); adjust to therapeutic aPTT (1.5–2.0 × control) and continue for at least 48 h or until revascularization [5][2]1
• Enoxaparin: 30 mg IV bolus then 1 mg/kg subcutaneous every 12 h; for CrCl < 30 mL/min use 1 mg/kg every 24 h, and for CrCl 30–60 mL/min reduce dose by 25 %; continue up to 8 days or until revascularization [5][1]
• Bivalirudin alternative regimen for early invasive strategy: 0.10 mg/kg IV loading dose followed by 0.25 mg/kg/h infusion; for CrCl < 30 mL/min use 1 mg/kg/h infusion [2][5]
• Fondaparinux: initial IV dose then 2.5 mg subcutaneous daily; continue up to 8 days or until revascularization; contraindicated if CrCl < 30 mL/min; when proceeding to PCI, add an anti‑IIa anticoagulant (UFH or enoxaparin) to prevent catheter thrombosis [1][2]5

Timing Considerations

• NSTEMI: give aspirin and an anticoagulant immediately on presentation; administer a P2Y12 inhibitor as early as possible—ticagrelor may be given before coronary anatomy is known, whereas prasugrel must be delayed until anatomy is known [2][3][4][1]
• STEMI: all antiplatelet and anticoagulant agents should be administered immediately after diagnosis; for a fibrinolytic strategy, give aspirin and clopidogrel before or together with the fibrinolytic agent 1

Glycoprotein IIb/IIIa Inhibitors (High‑Risk, Early‑Invasive Patients)

• Consider a glycoprotein IIb/IIIa inhibitor in troponin‑positive, high‑risk patients undergoing an early invasive strategy 2
• Eptifibatide: 180 µg/kg IV bolus (max 22.6 mg) then 2 µg/kg/min infusion; if CrCl ≤ 50 mL/min reduce infusion to 1.0 µg/kg/min 5
• Tirofiban: 12 µg/kg IV bolus then 0.14 µg/kg/min infusion; if CrCl < 30 mL/min use 6 µg/kg bolus plus 0.05 µg/kg/min infusion 5
• Abciximab: not recommended in elderly patients because of increased bleeding without added benefit 5

Critical Pitfalls to Avoid

• Never administer prasugrel before coronary anatomy is known – doing so markedly raises bleeding risk if urgent CABG is required [3][1]
• Do not use aspirin maintenance doses > 100 mg when ticagrelor is prescribed, as higher doses diminish ticagrelor efficacy [3][4]
• Always calculate anticoagulant doses on a weight‑based basis to avoid under‑ or overdosing [5][2]
• Check renal function before dosing enoxaparin, eptifibatide, or fondaparinux and apply the recommended dose adjustments or contraindications [5][2]
• When fondaparinux is used and the patient proceeds to PCI, add an anti‑IIa anticoagulant (UFH or enoxaparin) to prevent catheter‑related thrombosis 2
• Elderly patients (≥ 75 years) have a higher bleeding risk – consider a reduced clopidogrel loading dose (75 mg) with fibrinolysis and avoid prasugrel [5][1]
• Patients with body weight < 60 kg have increased bleeding risk with prasugrel – use a 5 mg maintenance dose if prasugrel is selected [3][4]

Acute Myocardial Infarction Management

Antiplatelet Medications

• The American College of Cardiology recommends an initial oral loading dose of 162-325 mg of aspirin for all AMI patients, as soon as possible 6
• The European Heart Journal suggests that if oral ingestion is not possible, intravenous (250-500 mg) or rectal administration of aspirin can be used 7, 6
• The American College of Cardiology recommends continuing with daily low-dose aspirin (75-100 mg) for maintenance therapy after the loading dose 6, 8
• The European Heart Journal recommends a loading dose of 300-600 mg of clopidogrel orally (preferably 600 mg for more rapid and stronger inhibition of platelet aggregation) 7, 9
• The European Heart Journal recommends a 60 mg oral loading dose of prasugrel, but it is contraindicated in patients with prior stroke/TIA, age ≥75 years, or weight <60 kg 10
• The European Heart Journal recommends a 180 mg oral loading dose of ticagrelor 10, 11
• The American Heart Association, as published in Circulation, recommends that P2Y12 inhibitors should be administered as early as possible in AMI patients, especially those undergoing PCI 9

Glycoprotein IIb/IIIa Inhibitors

• The American Heart Association, as published in Circulation, recommends an IV bolus of 0.25 mg/kg of abciximab, followed by maintenance infusion of 0.125 mcg/kg per minute (maximum 10 mg/min for 12 hours) 12, 7
• The American Heart Association, as published in Circulation, recommends an IV bolus of 180 mcg/kg of eptifibatide (not to exceed total initial bolus of 22.6 mg) 12, 10
• The European Heart Journal recommends a high-dose bolus regimen of tirofiban for primary PCI 10

Anticoagulants

• The European Heart Journal recommends an IV bolus of 70-100 U/kg of unfractionated heparin when no GPIIb/IIIa inhibitor is planned 10
• The European Heart Journal recommends a reduced dose of 50-60 U/kg of unfractionated heparin when used with GPIIb/IIIa inhibitors 10
• The American Heart Association, as published in Circulation, recommends an initial IV bolus of 30 mg of enoxaparin, followed by 1 mg/kg subcutaneously every 12 hours 12, 9
• The European Heart Journal recommends 0.75 mg/kg IV bolus of bivalirudin, followed by 1.75 mg/kg/hour infusion during PCI 10, 9

Fibrinolytic Agents

• The European Heart Journal recommends 1.5 million units of streptokinase over 30-60 minutes IV for fibrinolysis 7
• The European Heart Journal recommends 15 mg IV bolus of alteplase (t-PA), then 0.75 mg/kg over 30 min (max 50 mg), then 0.5 mg/kg over 60 min (max 35 mg) for fibrinolysis 7
• The European Heart Journal recommends 10 U + 10 U IV bolus of reteplase (r-PA) given 30 minutes apart for fibrinolysis 7
• The European Heart Journal recommends a single IV bolus of tenecteplase (TNK-tPA) based on weight (30-50 mg) for fibrinolysis 7

Important Considerations

• The American Heart Association, as published in Circulation, emphasizes that weight-based dosing is critical for many AMI medications to avoid both underdosing and overdosing 12, 10
• The American Heart Association, as published in Circulation, recommends assessing renal function for appropriate dosing of enoxaparin and eptifibatide 12, 9
• The American College of Cardiology recommends accurate timing of loading doses, with aspirin and P2Y12 inhibitors given as early as possible 6, 9
• The European Heart Journal recommends administering antiplatelet loading doses before primary PCI when possible 10
• The American Heart Association, as published in Circulation, warns that excessive dosing of GPIIb/IIIa inhibitors increases bleeding risk without additional benefit 12
• The American Heart Association, as published in Circulation, advises avoiding intravenous beta-blockers in patients with risk factors for cardiogenic shock 9